Upon stimulation with TLR9 agonist CpG ODNs, CCR9+ pDCs rapidly downregulate CCR9 from the original immature state and decrease the capacity to attenuate GVHD in vivo (53). This evidence concerns the gene CCR9 and graft versus host disease.